Johnson & Johnson Stock: Analyst Sees 11% Upside, Rates Buy

24/7 Wall St. has set a price target of $261.72 for Johnson & Johnson (NYSE:JNJ), representing an 11.28% upside from the current price of $235.18. The recommendation is "buy" with a 90% confidence level.

Rating Change

The source did not provide a prior rating for comparison. The current rating is "buy" with a new price target.

Analyst Rationale

Analysts believe JNJ has quietly become one of healthcare's most reliable compounders again, driven by strong oncology drug performance and a stable dividend. The valuation model is based on company fundamentals rather than temporary market factors.

Context

JNJ is currently trading at $235.18. No conflicting analyst opinions were mentioned. The stock is considered a defensive holding favored by income-focused investors. Recent stock performance was not discussed.

What We Conclude

The recommendation reflects confidence in JNJ's sustainable growth, but investors should note that valuations are based on projections that may not materialize.